Paroxysmal Cold Hemoglobinuria Latest Advances

Abdominal Pain as the First Manifestation of Rare Hematological Diseases: A Case Series

Journal: Harefuah

Published: September 03, 2026

Hematological diseases caused by excessive complement activation

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 30, 2026

Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria.

Journal: Journal of comparative effectiveness research

Published: August 24, 2026

Bone Marrow Failure Syndromes: Clinical and Genetic Characterization in TERT-associated Dyskeratosis Congenita.

Journal: The Israel Medical Association journal : IMAJ

Published: August 06, 2026

Anemia and Patient-Reported Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Real-World Observational Study.

Journal: EJHaem

Published: July 13, 2026

How Severe is Severe Enough? Organ Failure Rather Than Anemia Severity as a Potential Threshold for Complement Inhibition in Pediatric Paroxysmal Cold Hemoglobinuria: A Case Report.

Journal: Case reports in pediatrics

Published: July 02, 2026

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Journal: Hematology (Amsterdam, Netherlands)

Published: June 11, 2026

Complement inhibitor therapy should be available to patients with paroxysmal nocturnal hemoglobinuria throughout the world.

Journal: International journal of hematology

Published: June 09, 2026

Response to "Comment on 'Consensus of the hematology society of Taiwan on the management of paroxysmal nocturnal hemoglobinuria (PNH)'".

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: June 08, 2026

Terminal complement inhibition is associated with renal, hematologic, and thrombotic complications during septic shock: A global propensity score-matched cohort study.

Journal: Journal of critical care

Published: June 04, 2026

Concurrent Loss of PIGA and ZRSR2 in a Patient With Paroxysmal Nocturnal Hemoglobinuria and Myelodysplastic Neoplasm.

Journal: International journal of laboratory hematology

Published: June 03, 2026

How we Investigate Bone Marrow Failure Syndromes in Pediatric Patients.

Journal: Pediatric hematology and oncology

Published: June 01, 2026

Paroxysmal Cold Hemoglobinuria Latest Advances

Find the Latest Research About Paroxysmal Cold Hemoglobinuria

Abdominal Pain as the First Manifestation of Rare Hematological Diseases: A Case Series

Abdominal Pain as the First Manifestation of Rare Hematological Diseases: A Case Series

Hematological diseases caused by excessive complement activation

Hematological diseases caused by excessive complement activation

Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria.

Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria.

Bone Marrow Failure Syndromes: Clinical and Genetic Characterization in TERT-associated Dyskeratosis Congenita.

Bone Marrow Failure Syndromes: Clinical and Genetic Characterization in TERT-associated Dyskeratosis Congenita.

Anemia and Patient-Reported Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Real-World Observational Study.

Anemia and Patient-Reported Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Real-World Observational Study.

How Severe is Severe Enough? Organ Failure Rather Than Anemia Severity as a Potential Threshold for Complement Inhibition in Pediatric Paroxysmal Cold Hemoglobinuria: A Case Report.

How Severe is Severe Enough? Organ Failure Rather Than Anemia Severity as a Potential Threshold for Complement Inhibition in Pediatric Paroxysmal Cold Hemoglobinuria: A Case Report.

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Complement inhibitor therapy should be available to patients with paroxysmal nocturnal hemoglobinuria throughout the world.

Complement inhibitor therapy should be available to patients with paroxysmal nocturnal hemoglobinuria throughout the world.

Response to "Comment on 'Consensus of the hematology society of Taiwan on the management of paroxysmal nocturnal hemoglobinuria (PNH)'".

Response to "Comment on 'Consensus of the hematology society of Taiwan on the management of paroxysmal nocturnal hemoglobinuria (PNH)'".

Terminal complement inhibition is associated with renal, hematologic, and thrombotic complications during septic shock: A global propensity score-matched cohort study.

Terminal complement inhibition is associated with renal, hematologic, and thrombotic complications during septic shock: A global propensity score-matched cohort study.

Concurrent Loss of PIGA and ZRSR2 in a Patient With Paroxysmal Nocturnal Hemoglobinuria and Myelodysplastic Neoplasm.

Concurrent Loss of PIGA and ZRSR2 in a Patient With Paroxysmal Nocturnal Hemoglobinuria and Myelodysplastic Neoplasm.

How we Investigate Bone Marrow Failure Syndromes in Pediatric Patients.

How we Investigate Bone Marrow Failure Syndromes in Pediatric Patients.